Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 144,200 shares, an increase of 94.6% from the December 15th total of 74,100 shares. Approximately 1.2% of the shares of the stock are short sold. Based on an average trading volume of 55,400 shares, the days-to-cover ratio is presently 2.6 days.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Akari Therapeutics in a report on Monday. They set a “sell” rating for the company.

Akari Therapeutics Stock Down 0.4 %

AKTX stock opened at $1.21 on Tuesday. The firm has a 50-day moving average of $1.39 and a two-hundred day moving average of $2.58. Akari Therapeutics has a one year low of $0.90 and a one year high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.